I am a medical oncologist and translational researcher whose focus is on providing the best care possible to people with breast cancer. My dual role in the clinical setting and the laboratory allows me to work with my patients to develop more-effective, less-toxic therapies. I strongly believe that this is how we will change the future of cancer care.
Read more Read less
The ability to use a patient’s own immune system as a form of cancer treatment — immunotherapy — is revolutionizing how we attack many cancers. My goal is to bring these advances to people with breast cancer, a disease for which we are still discovering immunotherapy’s full potential. To this end, I am a member of the Center for Cell Engineering and the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering, where I am involved in both clinical trials and laboratory research that aim to bring the most promising immunotherapies to our patients. My expertise is in cellular therapy and genetic engineering, immune-stimulating antibodies and hormones (also called cytokines), and cancer vaccines.
Like many others, my family has been impacted by cancer. I have firsthand experience with how devastating a cancer diagnosis can be, and this guides every interaction I have with my patients and their families. It’s my goal to provide them with a full understanding of the nature of their disease, the treatment options available, and the evidence that supports these options. I believe it’s critical to present what can be an overwhelming amount of information and medical jargon in a way that makes sense.
In addition to empowering my patients with knowledge and understanding, I also want to empower them by providing clear ways of accessing and communicating with me and other members of their care team throughout their treatment and follow-up care. I never want my patients to feel isolated or alone. This communication and collaboration helps us focus on making people feel physically better and confident that they are receiving a treatment plan tailored to their individual needs and goals.
- Clinical Expertise: Cancer Immunotherapy; Cellular therapy; Breast Medicine
- Awards and Honors: Fellows Award for Research Excellence, National Institutes of Health (2013); Outstanding Postdoctoral Fellow, National Cancer Institute (2011)
- Languages Spoken: English
- Education: MD, Emory University School of Medicine
- Residencies: The Johns Hopkins Hospital
- Fellowships: National Cancer Institute; National Institutes of Health
- Board Certifications: Internal Medicine; Medical Oncology
Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med. 2016 Jan;22(1):26-36. PMID: 26735408
Klebanoff CA, Restifo NP. Customizing Functionality and Payload Delivery for Receptor-Engineered T Cells. Cell. 2016 Oct 6;167(2):304-306. PMID: 27716501
Klebanoff CA, Scott CD, Leonardi AJ, Yamamoto TN, Cruz AC, Ouyang C, Ramaswamy M, Roychoudhuri R, Ji Y, Eil RL, Sukumar M, Crompton JG, Palmer DC, Borman ZA, Clever D, Thomas SK, Patel S, Yu Z, Muranski P, Liu H, Wang E, Marincola FM, Gros A, Gattinoni L, Rosenberg SA, Siegel RM, Restifo NP. Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. J Clin Invest. 2016 Jan;126(1):318-34. PMID: 26657860
Read more Read less
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Read more Read less
Clinical Trials Led by Christopher A. Klebanoff
Clinical Trials Co-Investigated by Christopher A. Klebanoff
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more